Journal article
Head-to-head comparison of11C-PiB and18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia
CC Rowe, S Pejoska, RS Mulligan, G Jones, JG Chan, S Svensson, Z Cseleńyi, CL Masters, VL Villemagne
Journal of Nuclear Medicine | Published : 2013
Abstract
11C-Pittsburgh compound-B (11C-PiB) is the benchmark radiotracer for imaging of β-amyloid (Aβ) plaque in Alzheimer disease (AD). 18F-labeled Aβ tracers subsequently developed for clinical use show higher nonspecific white matter binding and, in some cases, lower cortical binding in AD that could lead to less accurate interpretation of scans. We compared the cortical and white matter binding of a new 18F- labeled Aβ tracer, 18F-AZD4694 (recently renamed NAV4694), with 11C-PiB in the same subjects. Methods: Forty-five participants underwent PET imaging with 11C-PiB and 18F-AZD4694 (25 healthy elderly controls [HCs], 10 subjects with mild cognitive impairment, 7 subjects with probable AD, and 3..
View full abstractGrants
Awarded by National Institute on Aging
Funding Acknowledgements
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. Christopher C. Rowe was a consultant for Astra Zeneca. Drs. Samuel Svensson and Zsolt Cselenyi are or were employees of Astra Zeneca at the time of this study. This work was supported in part by a grant from Astra Zeneca and by the Austin Hospital Medical Research Foundation. No other potential conflict of interest relevant to this article was reported.